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Introduction 
Refsum disease (or heredopathia atactica 
polyneuritiformis) is an autosomal recessive 
disorder caused in most instances by 
mutations in the gene (PhyH) encoding the 
enzyme phytanoyl-CoA hydroxylase, 
located on chromosome 10pter-p11.2.1,2 
These mutations lead to the accumulation of 
phytanic acid in affected patients. The 
mainstay of treatment is a reduction in the 
dietary phytanic acid intake. The following 
case illustrates an aggressive progression of 
the disease in a patient who was compliant 
with the dietary restrictions. 
 
Case Report 
A 33-year-old white female, had a 
history of progressive loss of vision and 
hearing since the age of 20, cardiomyopathy, 
cardiac arrhythmias, gastroparesis, urge 
incontinence, decreased bone mass, bilateral 
hip replacement, multiple surgical 
interventions on the right ankle, and one 
surgical intervention on the right knee. At 
the age of 27, she was diagnosed with 
Refsum disease by associating the 
shortening of the 4th metatarsals bilaterally 
and the retinitis pigmentosa, along with a 
high phytanic acid level.  She was started on 
the appropriate diet consisting of restrictions 
on green vegetables, meats from ruminating 
animals, and dairy products.  
Since the age of 30, the patient was 
hospitalized four times at another facility for 
acute decompensation of her disease.  
During  each hospitalization,  she underwent 
 
five sessions of plasmapheresis. During her 
last hospitalization, her phytanic level was 
105.5umol/L (reference range : ≤ 9.88).  It 
decreased to zero after the completion of 
four sessions of plasmapheresis.  She took 
ibuprofen 800 mg by mouth every eight 
hours during her hospital stay at the other 
facility.  
The patient presented to the emergency 
department at our facility for acute 
exacerbation of her disease, including retro-
orbital headaches, chest pain, nausea, 
vomiting, diarrhea, urinary incontinence, 
diffuse muscle aches, and weakness that had 
increased in intensity over two weeks. A 
detailed history revealed that she was 
compliant with her diet, but had a chronic 
ibuprofen intake for recurrent tension 
headaches. She was never told that 
ibuprofen is contraindicated in Refsum 
disease. The patient improved significantly 
after five sessions of plasmapheresis and 
discontinuation of ibuprofen.  
 
Discussion 
Branched-chain fatty acids are common 
in the human diet and related structures are 
common and occur in some drugs, such as  
ibuprofen (Figure 1).3  The most common 
branched-chain fatty acid is phytanic acid, 
found in some meats and dairy products. 
Normally, it is metabolized by activation to 
its CoA ester, phytanoyl-CoA, then alpha-
oxidation to pristanic acid.4  
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Figure 1.  Peroxisomal degradation of phytanic acid to pristanic acid.  [Figure from MD Lloyd 
and MD Threadgill.3]
 
 
Patients with Refsum disease are unable 
to degrade phytanic acid because of 
deficient activity of phytanoyl-CoA 
hydroxylase, a peroxisomal enzyme that 
catalyzes the first step of phytanic acid 
alpha-oxidation.4 Consequently, they 
accumulate significant amounts of phytanic 
acid in plasma and tissues, which are 
thought to be the major cause of the 
pathology of the disease.5 
Refsum disease is characterized 
clinically by atypical retinitis pigmentosa, 
peripheral polyneuropathy, cerebellar ataxia, 
anosmia, cardiomyopathy, conduction 
abnormalities, icthyosis, hyperkeratosis 
plantaris and palmaris, and epiphyseal 
dysplasia leading to characteristic shortening 
of the fourth toe, hammer toe, pes cavus, 
and osteochondritis.4-6 The characteristic 
findings are slow conduction velocities on 
nerve conduction studies, elevated 
cerebrospinal fluid protein concentration 
(100 to 600 mg/dl) without an increase in 
cells, grossly abnormal electroretinogram, 
onion bulb formation and targetoid 
inclusions in Schwann cells on nerve biopsy,  
 
 
and plasma levels of phytanic acid of > 800 
mmol.4-7  
Treatment consists of strict reduction in 
dietary phytanic acid intake to 10-20mg/day 
(daily average: 50-100mg).7 Plasma 
exchange can be considered if dietary 
control is inadequate.8   This approach halts 
the progression of the disease,  but does  not 
reverse neurologic abnormalities com-
pletely.  Ichthyosis, sensory neuropathy, and 
ataxia resolve in approximately that order, 
and electrocardiographic abnormalities may 
improve.  However, treatment may not 
affect retinitis pigmentosa, hearing 
impairment, or anosmia.7-9 
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